You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

The Use of Chemotherapy and Growth Factors in Older Patients with Newly Diagnosed, Advanced Stage, Aggressive Histology Non-Hodgkin's Lymphoma

Version: 2 ID: 6-7 Version 2 juin 2013
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
T. Kouroukis, G. Browman, R. Meyer , Hematology Disease Site Group

Patient Population

Patients older than age 60 who have newly diagnosed, advanced-stage, aggressive histology non-Hodgkin’s lymphoma, an Eastern Cooperative Oncology Group (ECOG) performance status of less than 4 and no significant comorbid illnesses.

Intended Guideline Users

Hematologists and oncologists treating patients older than age 60 who have newly diagnosed, advanced-stage, aggressive histology non-Hodgkin’s lymphoma.

Research Question(s)

  1. What treatment provides the optimum disease control and survival in older patients (at least 60 years of age) with newly diagnosed, advanced-stage, aggressive histology lymphoma?
  2. What are the toxicities associated with these treatments?
  3. What are the roles of granulocyte-colony stimulating factor or granulocyte macrophage-colony stimulating factor in combination with chemotherapy in these patients?
pdf download Full Report (PDF) (1.35 Mo)